<i>In‐vivo</i> efficacy of amodiaquine‐artesunate in children with uncomplicated <i>Plasmodium falciparum</i> malaria in western Kenya

Abstract

Although artemether-lumefantrine (Coartem) is the first line ACT in Kenya, amodiaquine-artesunate is registered as an option for treatment of uncomplicated P. falciparum and remains an effective alternative to Coartem in western Kenya. Continued amodiaquine monotherapy in the private sector may jeopardize the future use of amodiaquine-artesunate as an alternative artemisinin-based combination therapy.